Mood Emot.
2018 Nov;16(3):109-122. 10.0000/me.2018.16.3.109.
Korean Medication Algorithm for Bipolar Disorder 2018 : Children and Adolescents
- Affiliations
-
- 1Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University, Cheonan, Korea.
- 2Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- 3Department of Psychiatry, Naju National Hospital, Naju, Korea.
- 4Department of Psychiatry, Sacred Heart Hospital, Hallym University, Anyang, Korea.
- 5Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea.
- 6Department of Psychiatry, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
- 7Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University and Paik Institute for Clinical Research and Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea.
- 8Department of Psychiatry, Jeju National University Hospital, Jeju, Korea.
- 9Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation, Uiwang, Korea.
- 10Department of Psychiatry, Myongji Hospital, Goyang, Korea.
- 11Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea. kjoonmin@gmail.com
- KMID: 2434867
- DOI: http://doi.org/10.0000/me.2018.16.3.109
Abstract
OBJECTIVES
The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2014: Children and Adolescents.
METHODS
We performed the survey, using a questionnaire comprising 22 questions according to each situation, in children and adolescents with bipolar disorder.
RESULTS
First-line pharmacotherapeutic strategies for manic episode in children with bipolar disorder were a combination of mood stabilizer (MS) and an atypical antipsychotics (AAP), monotherapy with an AAP, risperidone, and aripiprazole. Aripiprazole was selected as first-line medication for depressive episode in children with bipolar disorder, and aripiprazole, and risperidone were selected as first-line at high-risk children. First-line pharmacotherapeutic strategies for manic episode in adolescents were a combination of MS and an AAP, monotherapy with an AAP valproate, lithium, risperidone (Treatment of Choice, TOC), aripiprazole, and quetiapine. First-line pharmacotherapeutic strategies for depressive episode in adolescents, were a combination of an atypical antipsychotics and lamotrigine, valproate, aripiprazole (TOC), risperidone, and quetiapine. For depressive episodes in adolescents at high risk for bipolar disorder, valproate, aripiprazole (TOC), and risperidone were selected as first-line medication.
CONCLUSION
We expect that the present KMAP-BP 2018-children and adolescents, is useful for clinicians to treat children and adolescents with bipolar disorder.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Development of Korean Medication Algorithm for Major Psychiatric Disorder
- Clinical Course of Bipolar Disorder in Children and Adolescents
- Korean Medication Algorithm Project for Bipolar Disorder 2022: Children and Adolescents
- Feasibility of Korean Medication Algorithm for Bipolar Disorder(I): Global Assessment
- Use of Atypical Antipsychotics in Attention-Deficit Hyperactivity Disorder
